SCHEMBL2153807

SCHEMBL2153807

CCC(=O)NC(c1ccccc1Cl)c1cc(Cl)c2cccnc2c1O

nearest known ligand 0.75

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALOX12 P18054 10/20 0.75
KDM4E B2RXH2 8/20 0.75
ADAMTS5 Q9UNA0 7/20 0.75
ADAMTS4 O75173 1/20 0.75
NPC1 O15118 5/20 0.74
RAB9A P51151 5/20 0.74
L3MBTL1 Q9Y468 3/20 0.74
MEN1 O00255 2/20 0.74
KMT2A Q03164 2/20 0.74
POLB P06746 2/20 0.74
LMNA P02545 1/20 0.74
SMN1; SMN2 Q16637 1/20 0.74
TDP1 Q9NUW8 1/20 0.74
HSP90AA1 P07900 1/20 0.72
HTT P42858 1/20 0.68
TP53 P04637 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24634764 0.93 HSP90AA1 (0.75) ALOX12KDM4EADAMTS5ADAMTS4NPC1
SCHEMBL30876624 0.93 HSP90AA1 (0.75) ALOX12KDM4EADAMTS5ADAMTS4NPC1
SCHEMBL1814298 0.90 ADAMTS5 (0.76) ALOX12KDM4EADAMTS5ADAMTS4NPC1
SCHEMBL2153098 0.90 NPC1 (0.80) ALOX12KDM4EADAMTS5ADAMTS4NPC1
SCHEMBL27790135 0.90 HSP90AA1 (0.76) ALOX12KDM4EADAMTS5ADAMTS4NPC1
SCHEMBL27790138 0.88 NPC1 (0.80) ALOX12ADAMTS5ADAMTS4NPC1RAB9A
SCHEMBL1813355 0.88 ADAMTS5 (0.79) ADAMTS5ADAMTS4RAB9AMEN1KMT2A
SCHEMBL2153206 0.87 ADAMTS5 (0.78) ALOX12KDM4EADAMTS5ADAMTS4NPC1
SCHEMBL5090799 0.87 ADAMTS5 (0.74) ADAMTS5ADAMTS4NPC1RAB9AL3MBTL1
SCHEMBL2153066 0.86 ALOX12 (0.86) ALOX12KDM4EADAMTS5NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression SIERRA SCIENCES, INC. (US) 2023-07-18 US disclosed
US-20120295890-A1 GLYCOSAMINOGLYCAN INHIBITORS Zacharon Pharmaceutical, Inc. (US) 2012-11-22 US disclosed
WO-2011082175-A2 GLYCOSAMINOGLYCAN INHIBITORS ZACHARON PHARMACEUTICALS, INC. (US) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295890-A1 GLYCOSAMINOGLYCAN INHIBITORS CSGALNACT1, FUT5, ST3GAL3 ALOX12 3731/4885KDM4E 4113/4885ADAMTS5 108/4885
US-11701374-B1 8-hydroxy quinoline derivatives for enhancing telomerase reverse transcriptase (TERT) expression TERT, TERF2, RNGTT ALOX12 3130/4885KDM4E 1300/4885ADAMTS5 2882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.